e-SPACE Heart Failure 2022
Published: 19 October 2022
Part 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
Part 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
Part 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
Part 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
Part 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
Part 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
Part 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
Part 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations Philippe Gabriel Steg, Shelley Zieroth, Milton Packer, Muthiah Vaduganathan, Cecilia Bahit , Subodh Verma
Part 1 | Session 7 Satellite Symposium: SGLT2 inhibition as foundational heart failure therapy: have we changed our practices? (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Andrew JS Coats, Shelley Zieroth, Stefan Anker, Daniela Tomasoni, Clara Saldarriaga
Part 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2) Giuseppe Galati, Altamash Y. Shaikh, Ewa Jankowska, George L Bakris, Stephan Von Haehling, Javed Butler
Part 1 | Session 9 Meet the expert: Best practice recommendations for the management of hyperkalemia (Supported by an educational grant from AstraZeneca) Clara Bonanad Lozano , Aaron Wong
Part 1 | Session 10 Meet the expert: Hyperkalaemia in patients with heart failure – dreadful side effect or manageable condition? (Supported by an unrestricted educational grant from CSL Vifor) Javed Butler, Ileana L Piña
Part 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs Mitja Lainscak, Ambarish Pandey, Faiez Zannad, Justin Ezekowitz, Ileana L Piña, Harriette Van Spall
Part 1 | Session 12 Meet the expert: Sex differences in advanced heart failure Andrew JS Coats, Aditi Nayak
Part 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF Antonio Ceriello, Naveed Sattar, Stefan Anker, Tammy Lyn Kindel, Andrew JS Coats, Jean-Philippe Minart
Part 2 | Session 1 Plenary Session 7: New technologies to manage your patients Vijay Chopra, Rishi Sethi, Friedrich Koehler, Jasper J Brugts, William T Abraham, Leor Perl
Part 2 | Session 2 Meet the expert: Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients (Sponsored by an unrestricted grant from CVRx) Stefan Anker, Marat Fudim
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Dr. Jouhra is based in London, where he works in the Department of Cardiology of St George’s University Hospital NHS Foundation Trust.
Dr. Jouhra began his cardiology training at King’s College Hospital in Oct 2011 as a Locum Appointment Trainee for 1 year. During that year, he developed a specialist interest in heart failure and went on to secure a further 2-year fellowship with a focus on this topic at King's. He obtained a cardiology NTN in the Kent Surrey & Sussex Deanery in 2014 and then went on to train at Princess Royal Haywards Heath Hospital and Eastbourne District General Hospital.
Dr. Jouhra spent his first subspecialty year in Heart Failure and Devices at St George’s Hospital London. His second subspecialty year was at St Thomas’ Hospital where he was independently implanting complex devices including CRTs.2
Dr Marat Fudim is a cardiologist, advanced heart failure specialist and assistant professoer at Durham, North Carolina, US. He has a clinical and research interest in heart failure, including advanced therapies such as mechanical assist devices or "heart pumps" and heart transplantation.
As part of his work, Dr Fudim also performs cardiac catheterisations to understand a patient’s disease.
William T Abraham
Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine
Prof Abraham is a College of Medicine Distinguished Professor. He has been recognized as one of the “Best Doctors in America” for 18 consecutive years.
His research has led to the approval/adoption of new heart failure therapies, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and mitral valve repair.
Prof Abraham has authored more than 1,000 original works and has been named a Clarivate Analytics Highly Cited Researcher and one of The World’s Most Influential Scientific Minds.
He received the 2017 Distinguished Scientist Award from the American College of Cardiology.
With his permission, Prof Abraham is contactable here.